2 New Article Summaries and Links to HCV articles

[Guest guest]

Coinfection - Top New Article

Little Overlap of Sexually Transmitted HCV between U.S. and Europe

SUMMARY› A phylogenetic analysis of more 200 hepatitis C virus (HCV) strains

from HIV positive gay and bisexual men revealed extensive clustering of related

viruses within U.S. cities, but little overlap between the East and West coasts,

or between the U.S. and Europe or Australia, according to findings presented at

the at the 18th Conference on Retroviruses and Opportunistic Infection (CROI

2011) this month in Boston.

Hepatitis B and C - Top New Articles

HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and

Non-responders

SUMMARY› Merck's investigational hepatitis C virus (HCV) protease inhibitor

boceprevir improved sustained response rates when combined with pegylated

interferon plus ribavirin in both previously untreated patients and those who

were non-responders or relapsers after prior therapy, according to 2 Phase 3

studies presented at the 18th Conference on Retroviruses and Opportunistic

Infections (CROI 2011) this month in Boston.

[Guest guest]

Coinfection - Top New Article

Little Overlap of Sexually Transmitted HCV between U.S. and Europe

SUMMARY› A phylogenetic analysis of more 200 hepatitis C virus (HCV) strains

from HIV positive gay and bisexual men revealed extensive clustering of related

viruses within U.S. cities, but little overlap between the East and West coasts,

or between the U.S. and Europe or Australia, according to findings presented at

the at the 18th Conference on Retroviruses and Opportunistic Infection (CROI

2011) this month in Boston.

Hepatitis B and C - Top New Articles

HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and

Non-responders

SUMMARY› Merck's investigational hepatitis C virus (HCV) protease inhibitor

boceprevir improved sustained response rates when combined with pegylated

interferon plus ribavirin in both previously untreated patients and those who

were non-responders or relapsers after prior therapy, according to 2 Phase 3

studies presented at the 18th Conference on Retroviruses and Opportunistic

Infections (CROI 2011) this month in Boston.

[Guest guest]

Coinfection - Top New Article

Little Overlap of Sexually Transmitted HCV between U.S. and Europe

SUMMARY› A phylogenetic analysis of more 200 hepatitis C virus (HCV) strains

from HIV positive gay and bisexual men revealed extensive clustering of related

viruses within U.S. cities, but little overlap between the East and West coasts,

or between the U.S. and Europe or Australia, according to findings presented at

the at the 18th Conference on Retroviruses and Opportunistic Infection (CROI

2011) this month in Boston.

Hepatitis B and C - Top New Articles

HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and

Non-responders

SUMMARY› Merck's investigational hepatitis C virus (HCV) protease inhibitor

boceprevir improved sustained response rates when combined with pegylated

interferon plus ribavirin in both previously untreated patients and those who

were non-responders or relapsers after prior therapy, according to 2 Phase 3

studies presented at the 18th Conference on Retroviruses and Opportunistic

Infections (CROI 2011) this month in Boston.

[Guest guest]

Coinfection - Top New Article

Little Overlap of Sexually Transmitted HCV between U.S. and Europe

SUMMARY› A phylogenetic analysis of more 200 hepatitis C virus (HCV) strains

from HIV positive gay and bisexual men revealed extensive clustering of related

viruses within U.S. cities, but little overlap between the East and West coasts,

or between the U.S. and Europe or Australia, according to findings presented at

the at the 18th Conference on Retroviruses and Opportunistic Infection (CROI

2011) this month in Boston.

Hepatitis B and C - Top New Articles

HCV Protease Inhibitor Boceprevir Improves Response for Treatment-Naive and

Non-responders

SUMMARY› Merck's investigational hepatitis C virus (HCV) protease inhibitor

boceprevir improved sustained response rates when combined with pegylated

interferon plus ribavirin in both previously untreated patients and those who

were non-responders or relapsers after prior therapy, according to 2 Phase 3

studies presented at the 18th Conference on Retroviruses and Opportunistic

Infections (CROI 2011) this month in Boston.